English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The sensitivity and the specificity of the photometric method for measuring urokinase and similar activities (thrombin, plasmin, trypsin, kallicrein) with an artificial chromogenic substrate (BZ – VAL – Gly – Arg – PNA = UK – Chromozym) were evaluated. For reference, a urokinase from Abbott Laboratories (Lot No. 143/291 Abbott, North Chicago, Illinois) was used. For a final concentration of UK – Chromozym of 0.1 x 10-3, 1 mU UK – Chromozym was found to be adequate to 17.2 U (Abbott). For 0.6 x 10-3 M, 1 mU UK – Chromozym was found to be in accordance to 10.4 U (Urokinase Abbott). In a preparation of 1 NIH thrombin (Boehringer Mannheim Diagnostica), an activity of 0.82 mU UK – Chromozym was measured. In plasmin (human, Kabi München, 1 Casein U), 84.8 mU UK – Chromozym were detected (1 Casein U per ml = 0.848 Δ OD/min.). For 1 NF trypsin, 19.7 mU Urokinase Chromozym were measured (1 Δ OD/min. = 0.197). For comparing the different activities in commercially available urokinase preparations (Sereno, Heidelberg, Urokinase Green Cross, Osaka), a Tris-Imidazol buffer was used (ionic strength 0.15; pH 8.4; containing 100 mg albumin, bovine per 1 and 10 U Aprotinin per 1). Thus, unspecific activities similar to urokinase activity were blocked (plasmin, trypsin, kallicrein, etc.). The same system was used for measuring the anti-urokinase-activity in the plasma of 25 healthy human volunteers and in 21 patients suffering from arterial occlusive diseases or from venous thrombosis before, during and after fibrinolysis therapy and before and after treatment with anticoagulants. These first results of clinical investigations will be discussed.

Photometric Measurement of Urokinase and Similar Activities with a New Artificial Chromogenic Substrate